Cargando…
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
Autores principales: | Jeng, Wen-Juei, Wong, Grace Lai-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931031/ https://www.ncbi.nlm.nih.gov/pubmed/36790353 http://dx.doi.org/10.1097/HC9.0000000000000060 |
Ejemplares similares
-
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021) -
Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021) -
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
por: Kim, Jin-Wook
Publicado: (2019) -
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
por: Hur, Moon Haeng, et al.
Publicado: (2023) -
Postpartum Hepatic Flares in Immune-Tolerant Pregnant Patients with Chronic Hepatitis B Virus Infection
por: Song, Myeong Jun
Publicado: (2022)